Search

Issue
Title
Authors
The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results
Snegovoy A.V., Kononenko I.B., Sorokina I.V., Berezina A.M., Prosianikova O.N.
Prevention of febrile neutropenia in oncological patients: real-world data
Sapozhnikov K.V., Sorokina I.V., Gusev A.V., Sableva N.A., Sokolova V.D., Tolkacheva D.G., Berezina A.M.
Use of granulocyte colony-stimulating factors in patients with HIV-associated lymphoproliferative diseases receiving cytotoxic therapy: Experience of a research center
Kremneva N.V., Dudina G.A., Tagieva E.U., Tokmakova A.A., Nemykin V.N.
Reduction of febrile neutropenia by using long-acting granulocyte colony-stimulating factors in patients with solid tumors receiving every-2-week chemotherapy
Kononenko I.B., Snegovoy A.V., Grebennikova O.P., Sel’chuk V.Y., Palchinskaia O.V.
Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study
Snegovoy A.V., Kononenko I.B., Radiukova I.M., Orlova S.A., Sultanbaev A.V., Dubovichenko D.M., Dergunov A.S., Saidullaeva A.F., Repina N.N., Gronskaia I.A., Rossokha E.I., Starostina T.V., Akimova O.V., Vasil'eva I.A., Godzhieva Z.A., Garanina O.I., Gorchkhanova K.I., Machekhina I.S., Gracheva A.S., Danilova A.E., Dmitrakova T.N., Dmitriev V.N., Dmitrochenko M.V., Dylinova O.V., El'kova V.O., Zhelezniak A.V., Zubova I.V., Ivanov A.N., Kaleikina L.P., Komoza I.V., Korolev D.N., Lebedeva L.N., Lebedinets A.A., Mamedguseinova N.N., Miagkova V.S., Matiushina E.I., Narovenkova K.V., Nikolaeva V.M., Novikov D.V., Polonskaia G.E., Rebrina O.V., Safronova M.A., Semenova A.S., Semenova I.A., Skotnikov R.A., Solov'eva E.P., Tat'ianenko A.N., Teterich A.A., Timin V.N., Tolmacheva I.A., Tiugina I.A., Khodkevich A.V., Tsarakhova F.V., Chapko I.S., Shegurova M.M., Shakurova N.R., Shalina A.I., Shumilkina E.A., Iakuba D.V., Ibragimova T.M., Feoktistova P.S., Sorokina I.V., Berezina A.M., Kiseleva P.V., Mironenko O.N., Prosianikova O.N.
Experience in prevention of neutropenia in patients with disseminated soft tissue sarcomas receiving polychemotherapy
Vladimirova L.Y., Mitashok I.S., Snezhko T.A., Samaneva N.Y., Storozhakova A.E., Kornilova I.S.
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study
Nesterova E.S., Saydullaeva A.F., Sherstnev D.G., Shelekhova T.V., Klitochenko T.Y., Khusainova G.N., Lysenko I.B., Lyalina I.S., Demchenkova M.V., Orlova S.A., Proydakov A.V., Betrozova М.V., Fadeeva N.V., Gofman A.A., Marchenko Y.M., Voloshin S.V., Pashneva E.A., Sarzhevskiy V.O., Babicheva A.R., Bondareva I.B., Glonina N.N., Ishchanov D.G., Poddubnaya I.V.
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast
Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S.
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A.
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study
Nesterova E.S., Saydullaeva A.F., Sherstnev D.G., Shelekhova T.V., Klitochenko T.Y., Khusainova G.N., Lysenko I.B., Lyalina I.S., Demchenkova M.V., Orlova S.A., Proydakov A.V., Betrozova M.V., Fadeeva N.V., Gofman A.A., Marchenko Y.M., Voloshin S.V., Pashneva E.A., Sarzhevskiy V.O., Ishchanov D.G., Poddubnaya I.V.
The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
Board E.
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy
Nesterova E.S., Klitochenko T.Y., Glonina N.N., Fadeeva N.V., Sannikova T.A., Lyalina I.S., Shelekhova T.V., Sherstnev D.G., Voloshin S.V., Sarzhevskii V.O., Hofman A.A., Ichshanov D.G., Poddubnaya I.V.
Cost-effectiveness of using granulocyte colony-stimulating factor in the treatment of uterine body leiomyosarcomas. A retrospective analysis
Saevets V.V., Kuzmin N.K., Shamanova A.Y., Mukhin A.A., Taratonov A.V.
1 - 13 of 13 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"